跳至主要内容
临床试验/NCT06223204
NCT06223204已完成不适用

GLEAM: Noninvasive Glucose Measurement Using Impedance Tomography - a Pilot Project

Insel Gruppe AG, University Hospital Bern1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2024年1月31日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
16
试验地点
1
主要终点
Change of the electrical impedance tomography (EIT) signal of the thoracic region across the glycemic trajectory.

研究概览

简要总结

The GLEAM study aims at assessing the potential of electrical impedance tomography (EIT) for noninvasive glucose measurement.

详细描述

Within the GLEAM study, paired samples of EIT and blood glucose measurements will be collected in individuals with type 1 diabetes during standardized euglycemia, hypoglycemia and hyperglycemia. These samples will be used to assess the potential of EIT for noninvasive glucose measurement and/or dysglycemia detection.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Written, informed consent
  • Type 1 Diabetes mellitus as defined by WHO for at least 6 months
  • Aged 18 - 60 years
  • HbA1c ≤ 9.0 %
  • Insulin treatment with good knowledge of insulin self-management
  • Use of a continuous (CGM) or flash glucose monitoring system (FGM)
  • Native language German or Swiss German

排除标准

  • Incapacity to give informed consent
  • Contraindications to insulin aspart (NovoRapid®)
  • Known allergies to adhesives of the EIT device (e.g., gel electrodes)
  • Pregnancy, breast-feeding or lack of safe contraception
  • Active heart, lung, liver, gastrointestinal, renal or psychiatric disease
  • Patients with implantable electronic devices (e.g., pacemaker or implantable cardioverter defibrillator (ICD)) or thoracic metal implants
  • Epilepsy or history of seizure
  • Active drug or alcohol abuse
  • Chronic neurological or ear-nose-and-throat (ENT) disease influencing voice or history of voice disorder
  • Thoracic or back deformities
  • Body mass index (BMI) >35.0 kg/m2
  • Open wounds, burns, or rashes on the upper thorax
  • Active smoking
  • Medication known to interfere with voice or to induce listlessness (e.g., opioids, benzodiazepines, etc.)

结局指标

主要结局

Change of the electrical impedance tomography (EIT) signal of the thoracic region across the glycemic trajectory.

时间窗: 5 hours

EIT signals will be collected at multiple frequencies between 50 kHz and 1 MHz from the thoracic region in euglycemia, hypoglycemia and hyperglycemia using a multi-channel EIT measurement device.

次要结局

  • Change of hypoglycemia symptoms across the glycemic trajectory.(5 hours)
  • Performance of a machine learning model to detect dysglycemia from the above-mentioned signals (EIT, symptoms, voice, physiological signals) quantified as sensitivity.(5 hours)
  • Voice parameters indicative of dysglycemia(5 hours)
  • Performance of a machine learning model to detect dysglycemia from the above-mentioned signals (EIT, symptoms, voice, physiological signals) quantified as area under the receiver operating characteristics curve (AUROC).(5 hours)
  • Performance of a machine learning model to detect dysglycemia from the above-mentioned signals (EIT, symptoms, voice, physiological signals) quantified as specificity.(5 hours)
  • Performance of the machine learning model to predict glucose values from the above-mentioned signals (EIT, symptoms, voice, physiological signals) quantified as root mean squared error (RMSE).(5 hours)
  • Performance of the machine learning model to predict glucose values from the above-mentioned signals (EIT, symptoms, voice, physiological signals) quantified as mean absolute relative difference (MARD).(5 hours)
  • Performance of the machine learning model to predict glucose values from the above-mentioned signals (EIT, symptoms, voice, physiological signals) using Bland-Altman plots.(5 hours)
  • Performance of the machine learning model to predict glucose values from the above-mentioned signals (EIT, symptoms, voice, physiological signals) using the Clarke Error Grid.(5 hours)
  • Change in cognitive performance across the glycemic trajectory.(5 hours)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验